What type of study is this?

September 10, 2025OphthaTherapy Therapies in OphthalmologyOpen Access

Patient treated with antimalarial drug under the supervision of a rheumatologist and ophthalmologist

View Full Paper

Ask AI

Bookmark

Authors

DSDorota SzumnyWroclaw Medical University AMAgnieszka MatuszewskaWroclaw Medical University

Discussion

Member takes

Implication

Assessment highlights ocular risks associated with antimalarial drugs in patients with systemic diseases, indicating the need for regular ophthalmological follow-up.

Key Points

Regular ophthalmological follow-up is crucial for patients taking antimalarial drugs to monitor potential ocular damage.
Maculopathy and retinopathy can lead to irreversible vision loss if not detected early in patients using chloroquine or hydroxychloroquine.
Risk factors for developing maculopathy include high doses and prolonged use of antimalarial drugs, alongside age and concurrent retinal disease.
Collaborative decision-making between rheumatologists and ophthalmologists is essential for managing ongoing treatment with these medications.

Cite This Study

Szumny et al. (2025) studied this question.

synapsesocial.com/papers/68c1c62654b1d3bfb60f178b https://doi.org/10.24292/01.ot.950525

View Full Paper

Ask AI

Bookmark

Implication

Assessment highlights ocular risks associated with antimalarial drugs in patients with systemic diseases, indicating the need for regular ophthalmological follow-up.

Patient treated with antimalarial drug under the supervision of a rheumatologist and ophthalmologist

Discussion

Member takes

Implication

Key Points

Cite This Study

Patient treated with antimalarial drug under the supervision of a rheumatologist and ophthalmologist

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider